UK court sends Pfizer/Flynn back to the CMA

The Court of Appeal of England and Wales has held that the UK’s competition enforcer did not sufficiently prove that two drug companies' prices were excessive, but backed the enforcer that it does not need to construct a hypothetical benchmark price.


Get unlimited access to all Global Competition Review content